Valproate-induced hyperammonemic encephalopathy: Imaging findings on diffusion-weighted MRI

European Neurology

Volumn 52, Issue 3, 2004, Pages 178-181

  Grubben, Bart ^a,b   De Jonghe, Peter ^a   Cras, Patrick ^a   Demey, Hendrik E ^a   Parizel, Paul M ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b AZ Stuivenberg ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GADOLINIUM PENTETATE MEGLUMINE; VALPROIC ACID;

ADULT; AMMONIA BLOOD LEVEL; ARTICLE; BRAIN DISEASE; CASE REPORT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; GLASGOW COMA SCALE; HUMAN; HYPERAMMONEMIA; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PRIORITY JOURNAL; SEIZURE; SOMNOLENCE; THREE DIMENSIONAL IMAGING;

BRAIN; BRAIN MAPPING; DIFFUSION MAGNETIC RESONANCE IMAGING; EPILEPSY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETT SYNDROME; VALPROIC ACID;

EID: 9244240339     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081861     Document Type: Article

References (17)

1. Löscher W: Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999;58:31-59.
2. Coulter DL, Allan RJ: Secondary hyperammonaemia: A possible mechanism for valproate encephalopathy. Lancet 1980;i:310-311.
3. Duarte J, Maccas S, Coria F, Fernandez E, Claveria LE: Valproate-induced coma: Case report and literature review. Ann Pharmacother 1993;27:582-583.
4. Sackellares JC, Lee Si, Dreifuss FE: Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 1979;20:697-703.
5. Baganz MD, Dross PE: Valproic acid-induced hyperammonemic encephalopathy: MR appearance. Am J Neuroradiol 1994;15:1779-1781.
6. 1H MR spectroscopy. Epilepsia 2002;43:1101-1105.
7. Perucca E: Pharmocological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
8. Hammer HM, Knake S, Schomburg U, Rosenow F: Valproate-induced hyperammomic encephalopathy in the presence of topiramate. Neurology 2000;54:230-232.
9. Warter JM, Marescaux C, Brandt C, et al: Sodium-valproate associated with phenobarbital: Effect on ammonia metabolism in humans. Epilepsia 1983;24:628-633.
10. Honeycutt D, Callahan K, Rutledge L, Evans B: Heterozygote ornithine transcarbamoylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 1999;42:666-668.
11. Kay JDS, Hilton-Jones D, Hyman N: Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet 1986;ii:1283-1284.
12. Duarte J, Macias S, Coria F, Fernandez, Claveria LE: Valproate-induced coma: Case report and literature review. Ann Pharmacother 1993;27:582-583.
13. Blindauer KA, Harrington G, Morris GL, Ho KC: Fulminant progression of demyelating disease after valproate-induced encephalopathy. Neurology 1998:51:292-295.
14. Albers GW: Diffusion-weighted MRI for evaluation of acute stroke. Neurology 1998;51:47-49.
15. Stadnik TW, Demaerel P, Luypaert RR, et al: Imaging tutorial: Differential diagnosis of bright lesions on diffusion-weighted MR images. Radiographics 2003;23:e7-e7.
16. Verotti A, Trotta D, Morgese G, Chiarelli F: Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002;14:367-373.
17. Takanashi JI, Barkovich AJ, Cheng SF, Kostiner D, Baker JC, Packman S: Brain. MR imaging in acute hyperammonemic encephalopathy from lateonset ornithine transcarbamylase deficiency. AJNR Am J Neuroradiol 2003;24:390-393.